U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. NanoBiotech Pharma - Close Out Letter 6/13/17
  1. Compliance Actions and Activities

CLOSEOUT LETTER

NanoBiotech Pharma 13/06/2017

NanoBiotech Pharma - Close Out Letter 6/13/17


NanoBiotech Pharma

  

Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 College Park, MD 20740 

June 13, 2017

Gary S. Mezo
NanoBiotech Pharma, Inc.
7512 Dr. Phillips Blvd.
Suite 50-240
Orlando, FL 32819

Dear Mr. Mezo:

The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter #446481, issued February 26, 2015. Based on our evaluation, it appears you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Latasha Robinson, Branch Chief
Dietary Supplement and Labeling Assessment Branch
Division of Enforcement
Office of Compliance
Center for Food Safety and Applied Nutrition